Track the 바이오다인 stock price and the full management transaction log of the company, a publicly traded company based in South Korea. Shares are quoted on KR KR, under the authority of DART (FSS). Operating in the Health Care sector, 바이오다인 has recorded 28 insider filings. Market capitalisation: €249.4bn. The latest transaction was disclosed on 13 July 2026 (Purchase). Among the most active insiders: 임욱빈. Every trade is accessible without an account.
28
Insider Decl.
n/a
Thresholds
n/a
7 ops.
Buy Volume
n/a
10 ops.
Sell Volume
7Σ signal
This score ranks the purchase within its own market. No market currently meets the historical allocation criteria, so signals remain watch-only. Not investment advice.
Fundamental score
Ranked 13,656 of 27,949 companies
52.6
score / 100
Value
32
Quality
73
FCF yld-2.0%
Earn yld0.4%
EV/EBITDA·
ROE3.3%
Gross mgn64%
Net mgn12%
Debt/EBITDA0.0x
Pillars2/3
Transparent value + quality ranking, distinct from the insider signal.
Σ
Sigma AI Analysis
Fundamental view, insider signal, bull and bear case, synthesis.
AI-generated analysis. Opinion, not investment advice. Not backtested. Built from public filings and financials. No price target, no buy or sell recommendation.
BioDine is a healthcare and pharmaceutical company listed on the XKRX market. It specializes in developing innovative solutions for the medical sector.